Marine biomedicine researchers decode structure of promising sea compound
Novel natural product yielding potential new ways to fight diseases
Scripps scientists collected cyanobacteria, tiny photosynthetic sea organisms, in Hoia Bay off Papua New Guinea in 2002 and recently discovered that the bacteria produce a compound with a structure previously unseen in biomedicine. The compound, which the researchers have dubbed hoiamide A, offers a novel template for drug development.
"We have seen some of hoiamide A's features in other molecules, but separately," said Alban Pereira, a postdoctoral researcher in Scripps' CMBB and a paper coauthor. "We believe this new template may be important because it's showing different mechanisms of action — different ways to interact with neurons, possibly with a good therapeutic effect for such diseases as epilepsy, hypoxia-ischemia and several neurodegenerative disorders."
In pharmacological tests conducted at Creighton University, Hoiamide A was shown to interact with the same important therapeutic target as analgesic, antiarrhythmic, antiepileptic and neuroprotective drugs.
Dan Edwards and Luke Simmons, former members of Gerwick's laboratory, collected a mixture of cyanobacteria species Lyngbya majuscula and Phormidium gracile in May 2002 at five- to 10-meters (16 to 33 feet) depth from Hoia Bay. Extractions of this sample were shown to have intriguing neurochemical properties in assays run at Creighton University's School of Medicine. Gerwick and Murray's laboratories then collaborated to isolate the neuroactive substance and characterize its extraordinarily complex chemical structure.
"Classically, what we know about the workings of the human nervous system has come largely from studies of different toxins on the function of model systems, such as in this case, the action of hoiamide A on nerve cells in petri dish cultures," said Gerwick. "The toxins serve as 'molecular tools' for manipulating cells at an extremely microscopic scale. Ultimately, by understanding how neurons work at this detailed level, and having a set of tools such as hoiamide A, we can envision the development of new, more effective treatments for such diverse conditions as epilepsy, pain control and memory and cognition enhancement. The natural world still has many valuable molecules left for us to discover and hopefully develop into new classes of medicines."
Topics
Organizations
Other news from the department science
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.